The Ki-67 protein (also known as MKI67) is a cellular marker for proliferation, [10] and can be used in immunohistochemistry. It is strictly associated with cell proliferation. During interphase, the Ki-67 antigen can be exclusively detected within the cell nucleus, whereas in mitosis most of the protein is relocated to the surface of the ...

Mar 17, 2025 · Ki-67 is a protein found in the nucleus of cancer cells that are actively growing and dividing. For breast cancer, Ki-67 is one of the main tumor biomarkers that your healthcare provider will check for when diagnosing, staging, and monitoring the cancer.

Ki-67 protein has been widely used as a proliferation marker for human tumor cells for decades. In recent studies, multiple molecular functions of this large protein have become better understood. Ki-67 has roles in both interphase and mitotic cells, and its cellular distribution dramatically changes during cell cycle progression.

In breast cancer development, the expression of Ki-67 is strongly associated with cancer proliferation and is a known indicator of prognosis and outcome. Ki-67 expression levels are also useful to inform treatment decision making in some cases. As a ...

A Ki-67 proliferation index over 30% is typically considered high. The Ki-67 proliferation index may be used to help predict how well some cancers, such as breast cancer, will respond to certain treatments, such as chemotherapy. Also called Ki-67 score.

Patients with Ki-67 higher than 15% exhibited higher incidence of metastasis and recurrence than those with Ki-67 less than 15% (P = 0.000). Conclusions: Ki-67 may be considered as a valuable biomarker in breast cancer patients.

Oct 23, 2024 · The KI-67 protein test is a diagnostic tool used in the field of oncology to measure the level of a protein called KI-67 in cancer cells. The KI-67 protein is a marker for cell proliferation, meaning it indicates how quickly cancer cells are dividing and growing.

Mar 14, 2022 · Her tumor had a higher level of a cancer-related gene known as Ki-67, indicating rapid reproduction of cancer cells. A mixed bag of clinical trial data has shown that certain levels of Ki-67 in breast tumors support better outcomes for patients who are treated with CDK inhibitors.

In breast cancer, the most widely practiced method for comparing proliferation between tumor samples involves the immunohistochemical assessment of Ki67 antigen (also known as antigen identified by monoclonal antibody Ki-67 [MKI67]), a nuclear marker expressed in all phases of the cell cycle other than the G0 phase.

Mar 19, 2025 · Ki67 immunohistochemistry (IHC) is widely used in pathology to assess tumor proliferation, providing valuable information for diagnosis, prognosis, and treatment planning. By detecting Ki67, a protein expressed during active cell division, this technique helps evaluate tumor growth and response to therapy.